CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 40 enrolled
Drug / intervention
Linagliptin +1 moredrug
Likely dose
Linagliptin 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02372630
NCT02372630Phase 4Completed
CompareCT.gov

The Effect of TRADJENTA ® (LINAGLIPTIN) on Inflammation, Oxidative Stress and Insulin Resistance in Obese Type 2 Diabetes Subjects

University at Buffalo·interventional·Posted Feb 26, 2015·Updated Feb 21, 2023

In Brief

A Phase 4 clinical trial evaluating Linagliptin and Placebo for Type 2 Diabetes. Completed, enrolled 40 participants across 1 site.

Detailed Summary

This is a single center, prospective randomized double blind, parallel and placebo controlled study to evaluate oxidative stress and inflammation before and after treatment with linagliptin for 12 weeks. We will also, testing whether Linagliptin is an insulin sensitizer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes
CountriesUnited States
CollaboratorsKaleida Health

Timeline

Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedFeb 26, 2015
Enrollment StartMay 23, 2014
Primary CompletionFeb 1, 2018
Study CompletionMay 1, 2018
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 11.3 years ago

Interventions

Linagliptindrug

5 mg daily oral tablets of linagliptin

Placebodrug

matching placebo giving orally daily